Topotecan-d5

• Description:

  Topotecan-d5 is the deuterium labeled Topotecan. Topotecan (SKF 104864A; NSC 609669) is a Topoisomerase I inhibitor. The IC50 values of Topotecan at 24 h are 2.73±0.25 μM of U251 cells, 2.95±0.23 μM of U87 cells, 5.46±0.41 μM of GSCs-U251 and 5.95±0.24 μM of GSCs-U87[1][2].

• Product Name Alternative:

  SKF 104864A-d5; NSC 609669-d5

• UNSPSC:

  12352005

• Target:

  Autophagy; Isotope-Labeled Compounds; Topoisomerase

• Related Pathways:

  Autophagy; Cell Cycle/DNA Damage; Others

• Field of Research:

  Cancer

• Solubility:

  10 mM in DMSO

• Smiles:

  [2H]C([2H])([2H])C([2H])([2H])[C@@]1(C2=C(COC1=O)C(N3C(C(C(C3)=CC4=C5CN(C)C)=NC4=CC=C5O)=C2)=O)O

• Molecular Formula:

  C23H18D5N3O5

• Molecular Weight:

  426.48

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Zhang FL, et al. PLoS One. 2013 Nov 26;8 (11) :e81815.Topoisomerase I inhibitors, Shikonin and Topotecan, inhibit growth and induce apoptosis of glioma cells andglioma stem cells.|[3]Kumar S, et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res. 2011 Sep 1;17 (17) :5656-67.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  [1133355-98-2]